2-phenylethanol Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86
    Glaxo Smith salbutamol
    Number of H bonds contacts established by <t>salbutamol</t> with wild (red) and T164I β2AR (black) in each frame of simulation. Reduced H bond contacts for T164I variant can be observed.
    Salbutamol, supplied by Glaxo Smith, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/salbutamol/product/Glaxo Smith
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    salbutamol - by Bioz Stars, 2021-05
    86/100 stars
      Buy from Supplier

    98
    Millipore salbutamol
    Number of H bonds contacts established by <t>salbutamol</t> with wild (red) and T164I β2AR (black) in each frame of simulation. Reduced H bond contacts for T164I variant can be observed.
    Salbutamol, supplied by Millipore, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/salbutamol/product/Millipore
    Average 98 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    salbutamol - by Bioz Stars, 2021-05
    98/100 stars
      Buy from Supplier

    99
    Millipore 2 phenylethanol
    Number of H bonds contacts established by <t>salbutamol</t> with wild (red) and T164I β2AR (black) in each frame of simulation. Reduced H bond contacts for T164I variant can be observed.
    2 Phenylethanol, supplied by Millipore, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/2 phenylethanol/product/Millipore
    Average 99 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    2 phenylethanol - by Bioz Stars, 2021-05
    99/100 stars
      Buy from Supplier

    86
    MDPI albuterol mdpi
    Patient disposition for the integrated safety population. <t>MDPI,</t> multidose dry powder inhaler; QID, four times a day. a One patient in one of the 12-week double-blind studies took both <t>albuterol</t> MDPI and placebo MDPI in error and was therefore included in both treatment groups of the safety population. Thus, 321 patients were treated with albuterol MDPI 180 µg QID and 333 patients were treated with placebo MDPI.
    Albuterol Mdpi, supplied by MDPI, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/albuterol mdpi/product/MDPI
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    albuterol mdpi - by Bioz Stars, 2021-05
    86/100 stars
      Buy from Supplier


    N/A
    2 Phenylethanol
      Buy from Supplier



    Image Search Results


    Number of H bonds contacts established by salbutamol with wild (red) and T164I β2AR (black) in each frame of simulation. Reduced H bond contacts for T164I variant can be observed.

    Journal: PLoS ONE

    Article Title: Molecular dynamic simulations reveal suboptimal binding of salbutamol in T164I variant of β2 adrenergic receptor

    doi: 10.1371/journal.pone.0186666

    Figure Lengend Snippet: Number of H bonds contacts established by salbutamol with wild (red) and T164I β2AR (black) in each frame of simulation. Reduced H bond contacts for T164I variant can be observed.

    Article Snippet: While the quest for developing structure based agonist selectively targeting β2AR was in the demand, Sir David Jack and colleagues at Allen and Hanburys (now part of GlaxoSmithKline) introduced salbutamol [ ].

    Techniques: Variant Assay

    “Ligand fit in protein” RMSD for salbutamol in wild (red) and T164I β2AR (black) projected at a simulation trajectory of 10 ns.

    Journal: PLoS ONE

    Article Title: Molecular dynamic simulations reveal suboptimal binding of salbutamol in T164I variant of β2 adrenergic receptor

    doi: 10.1371/journal.pone.0186666

    Figure Lengend Snippet: “Ligand fit in protein” RMSD for salbutamol in wild (red) and T164I β2AR (black) projected at a simulation trajectory of 10 ns.

    Article Snippet: While the quest for developing structure based agonist selectively targeting β2AR was in the demand, Sir David Jack and colleagues at Allen and Hanburys (now part of GlaxoSmithKline) introduced salbutamol [ ].

    Techniques:

    The overlapping cartoon depicts binding cavities of wild (green solid) and T164I (red mesh) β2AR. Volume of the cavity in wild β2AR is 404.48 Å 3 , upon substitution the cavity expands to 520.70 Å 3 . Poses of salbutamol (Sea green in wild, and pink in T164I variant) are shown in the binding cavity.

    Journal: PLoS ONE

    Article Title: Molecular dynamic simulations reveal suboptimal binding of salbutamol in T164I variant of β2 adrenergic receptor

    doi: 10.1371/journal.pone.0186666

    Figure Lengend Snippet: The overlapping cartoon depicts binding cavities of wild (green solid) and T164I (red mesh) β2AR. Volume of the cavity in wild β2AR is 404.48 Å 3 , upon substitution the cavity expands to 520.70 Å 3 . Poses of salbutamol (Sea green in wild, and pink in T164I variant) are shown in the binding cavity.

    Article Snippet: While the quest for developing structure based agonist selectively targeting β2AR was in the demand, Sir David Jack and colleagues at Allen and Hanburys (now part of GlaxoSmithKline) introduced salbutamol [ ].

    Techniques: Binding Assay, Variant Assay

    Timeline representation of ligand— Receptor interactions. Residues interacting (all the interactions including H-bonds, Hydrophobic, Ionic, Water bridges) with salbutamol in (A) wild and (B) T164I variant of β2AR.

    Journal: PLoS ONE

    Article Title: Molecular dynamic simulations reveal suboptimal binding of salbutamol in T164I variant of β2 adrenergic receptor

    doi: 10.1371/journal.pone.0186666

    Figure Lengend Snippet: Timeline representation of ligand— Receptor interactions. Residues interacting (all the interactions including H-bonds, Hydrophobic, Ionic, Water bridges) with salbutamol in (A) wild and (B) T164I variant of β2AR.

    Article Snippet: While the quest for developing structure based agonist selectively targeting β2AR was in the demand, Sir David Jack and colleagues at Allen and Hanburys (now part of GlaxoSmithKline) introduced salbutamol [ ].

    Techniques: Variant Assay

    Interactions of Salbutamol docked in the agonist binding site. H bond and pi-pi networks of salbutamol in (A) wild and (B) T164I β2AR. Black discontinuous lines are H bonds, blue line represent pi-pi interactions.

    Journal: PLoS ONE

    Article Title: Molecular dynamic simulations reveal suboptimal binding of salbutamol in T164I variant of β2 adrenergic receptor

    doi: 10.1371/journal.pone.0186666

    Figure Lengend Snippet: Interactions of Salbutamol docked in the agonist binding site. H bond and pi-pi networks of salbutamol in (A) wild and (B) T164I β2AR. Black discontinuous lines are H bonds, blue line represent pi-pi interactions.

    Article Snippet: While the quest for developing structure based agonist selectively targeting β2AR was in the demand, Sir David Jack and colleagues at Allen and Hanburys (now part of GlaxoSmithKline) introduced salbutamol [ ].

    Techniques: Binding Assay

    Trajectory analysis of salbutamol in complex with wild and T164I β2AR. (A) RMSD of salbutamol with respect to the reference conformation in wild and T164I β2AR. (B) ‘Fit on protein' line shows atomic fluctuations (RMSF) with respect to the receptor. Corresponding atoms of salbutamol is shown as 2D structure in the top panel. (C) Solvent accessible surface area of salbutamol in course of simulation. Trajectory lines for wild and T164I β2AR are represented in red and black color respectively.

    Journal: PLoS ONE

    Article Title: Molecular dynamic simulations reveal suboptimal binding of salbutamol in T164I variant of β2 adrenergic receptor

    doi: 10.1371/journal.pone.0186666

    Figure Lengend Snippet: Trajectory analysis of salbutamol in complex with wild and T164I β2AR. (A) RMSD of salbutamol with respect to the reference conformation in wild and T164I β2AR. (B) ‘Fit on protein' line shows atomic fluctuations (RMSF) with respect to the receptor. Corresponding atoms of salbutamol is shown as 2D structure in the top panel. (C) Solvent accessible surface area of salbutamol in course of simulation. Trajectory lines for wild and T164I β2AR are represented in red and black color respectively.

    Article Snippet: While the quest for developing structure based agonist selectively targeting β2AR was in the demand, Sir David Jack and colleagues at Allen and Hanburys (now part of GlaxoSmithKline) introduced salbutamol [ ].

    Techniques:

    Total contacts (H-bonds, Hydrophobic, Ionic, Water bridges) of salbutamol with wild (red) and T164I (black) β2AR recorded at each frame of simulation. Declined contacts of salbutamol in T164I variant are apparent.

    Journal: PLoS ONE

    Article Title: Molecular dynamic simulations reveal suboptimal binding of salbutamol in T164I variant of β2 adrenergic receptor

    doi: 10.1371/journal.pone.0186666

    Figure Lengend Snippet: Total contacts (H-bonds, Hydrophobic, Ionic, Water bridges) of salbutamol with wild (red) and T164I (black) β2AR recorded at each frame of simulation. Declined contacts of salbutamol in T164I variant are apparent.

    Article Snippet: While the quest for developing structure based agonist selectively targeting β2AR was in the demand, Sir David Jack and colleagues at Allen and Hanburys (now part of GlaxoSmithKline) introduced salbutamol [ ].

    Techniques: Variant Assay

    Molecular interaction diagrams of salbutamol deduced from molecular docking. (A) Salbutamol in Wild and (B) Salbutamol in T164I β2AR. Residues in green participate in van der Waals interaction, residues in pink form electrostatic interactions with the salbutamol. Hydrogen bonds are shown as blue (acceptor) and pink (donor) arrows. Pi-pi interactions are shown with orange solid line.

    Journal: PLoS ONE

    Article Title: Molecular dynamic simulations reveal suboptimal binding of salbutamol in T164I variant of β2 adrenergic receptor

    doi: 10.1371/journal.pone.0186666

    Figure Lengend Snippet: Molecular interaction diagrams of salbutamol deduced from molecular docking. (A) Salbutamol in Wild and (B) Salbutamol in T164I β2AR. Residues in green participate in van der Waals interaction, residues in pink form electrostatic interactions with the salbutamol. Hydrogen bonds are shown as blue (acceptor) and pink (donor) arrows. Pi-pi interactions are shown with orange solid line.

    Article Snippet: While the quest for developing structure based agonist selectively targeting β2AR was in the demand, Sir David Jack and colleagues at Allen and Hanburys (now part of GlaxoSmithKline) introduced salbutamol [ ].

    Techniques:

    Contact fractions of ligand-receptor interactions in course of simulation. Simulation interaction diagram showing contact fractions of residues interacting with salbutamol in (A) wild and (B) T164I variant of β2AR.

    Journal: PLoS ONE

    Article Title: Molecular dynamic simulations reveal suboptimal binding of salbutamol in T164I variant of β2 adrenergic receptor

    doi: 10.1371/journal.pone.0186666

    Figure Lengend Snippet: Contact fractions of ligand-receptor interactions in course of simulation. Simulation interaction diagram showing contact fractions of residues interacting with salbutamol in (A) wild and (B) T164I variant of β2AR.

    Article Snippet: While the quest for developing structure based agonist selectively targeting β2AR was in the demand, Sir David Jack and colleagues at Allen and Hanburys (now part of GlaxoSmithKline) introduced salbutamol [ ].

    Techniques: Variant Assay

    Patient disposition for the integrated safety population. MDPI, multidose dry powder inhaler; QID, four times a day. a One patient in one of the 12-week double-blind studies took both albuterol MDPI and placebo MDPI in error and was therefore included in both treatment groups of the safety population. Thus, 321 patients were treated with albuterol MDPI 180 µg QID and 333 patients were treated with placebo MDPI.

    Journal: The Journal of Asthma

    Article Title: Twelve- and 52-week safety of albuterol multidose dry powder inhaler in patients with persistent asthma

    doi: 10.3109/02770903.2015.1070862

    Figure Lengend Snippet: Patient disposition for the integrated safety population. MDPI, multidose dry powder inhaler; QID, four times a day. a One patient in one of the 12-week double-blind studies took both albuterol MDPI and placebo MDPI in error and was therefore included in both treatment groups of the safety population. Thus, 321 patients were treated with albuterol MDPI 180 µg QID and 333 patients were treated with placebo MDPI.

    Article Snippet: Of the 156 patients who were treated with albuterol MDPI during the 12-week double-blind phase and continued on albuterol MDPI during the 40-week open-label phase, four experienced serious adverse events during the 40-week open-label phase.

    Techniques:

    Study design of three pivotal phase three studies (ABS-AS-301, ABS-AS-304 and ABS-AS-307). HFA, hydrofluoroalkane; MDI, metered-dose inhaler; MDPI, multidose dry powder inhaler; PRN, as needed; QID, four times a day. a All patients were provided with an albuterol HFA MDI to use as needed for breakthrough asthma symptoms. b Final follow-up of adverse events was conducted 3 (±1) days after the last treatment visit.

    Journal: The Journal of Asthma

    Article Title: Twelve- and 52-week safety of albuterol multidose dry powder inhaler in patients with persistent asthma

    doi: 10.3109/02770903.2015.1070862

    Figure Lengend Snippet: Study design of three pivotal phase three studies (ABS-AS-301, ABS-AS-304 and ABS-AS-307). HFA, hydrofluoroalkane; MDI, metered-dose inhaler; MDPI, multidose dry powder inhaler; PRN, as needed; QID, four times a day. a All patients were provided with an albuterol HFA MDI to use as needed for breakthrough asthma symptoms. b Final follow-up of adverse events was conducted 3 (±1) days after the last treatment visit.

    Article Snippet: Of the 156 patients who were treated with albuterol MDPI during the 12-week double-blind phase and continued on albuterol MDPI during the 40-week open-label phase, four experienced serious adverse events during the 40-week open-label phase.

    Techniques: